sb 202190 has been researched along with Blood Poisoning in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Excerpt | Relevance | Reference |
|---|---|---|
| " SB-202190 and SN-50, in combination with antibiotic, resulted in a significant survival benefit in the CLP model (P = 0." | 1.35 | NF-kappaB and p38 MAPK inhibition improve survival in endotoxin shock and in a cecal ligation and puncture model of sepsis in combination with antibiotic therapy. ( O'Sullivan, AW; Redmond, HP; Wang, JH, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Sullivan, AW | 1 |
| Wang, JH | 1 |
| Redmond, HP | 1 |
1 other study available for sb 202190 and Blood Poisoning
| Article | Year |
|---|---|
NF-kappaB and p38 MAPK inhibition improve survival in endotoxin shock and in a cecal ligation and puncture model of sepsis in combination with antibiotic therapy.
Topics: Animals; Anti-Bacterial Agents; Blotting, Western; Cecum; Drug Therapy, Combination; Electrophoretic | 2009 |